AI医疗人气股，4.68亿元募资到期未还

Core Viewpoint - The article discusses the recent developments regarding Seli Medical, highlighting its financial difficulties and regulatory scrutiny, while also noting its association with Huawei's AI medical initiatives. Group 1: Financial Issues - Seli Medical announced that it has three overdue payments totaling 468 million yuan due to industry policy impacts and slower-than-expected accounts receivable collection [1] - The company expects a net loss for the fiscal year 2024, projecting a loss between 210 million yuan and 250 million yuan, with a net profit loss after deductions estimated between 145 million yuan and 190 million yuan [3] Group 2: Regulatory Scrutiny - On March 25, 2024, Seli Medical received a notice from the China Securities Regulatory Commission (CSRC) regarding an investigation into suspected violations of information disclosure laws [1] Group 3: Market Performance and Partnerships - Following its association with Huawei's AI medical concept, Seli Medical's stock experienced a surge, hitting a closing price of 12.08 yuan per share and a total market capitalization of 2.307 billion yuan as of March 12 [1] - Seli Medical signed a cooperation agreement with Huawei on February 21, focusing on the development of AI-assisted diagnostic solutions [2]